Differences in the prophylactic effect of serum lithium levels on depression and mania in bipolar disorder: A dose-response meta-analysis
- PMID: 35158229
- DOI: 10.1016/j.euroneuro.2022.01.112
Differences in the prophylactic effect of serum lithium levels on depression and mania in bipolar disorder: A dose-response meta-analysis
Abstract
The optimal serum lithium levels for preventing the recurrence of mood episodes in bipolar disorder are controversial, especially when polarity is considered. The present study aimed to comprehensively examine the dose-response relationship between lithium concentration and risk of recurrence of mood episodes. We conducted a systematic search of major databases before January 2021 (PROSPERO: CRD42021235812). A one-stage, random-effects, restricted cubic splines model was used to estimate the dose-response relationship between lithium concentration and risk of recurrence of any or specific mood episodes (depression or mania). The effect size is shown as odds ratio (OR). Our meta-analysis included six randomised controlled trials with a total of 975 participants. The dose-response curve showed that increased serum concentrations were associated with a gradual decrease in the risk of any mood episodes (OR 0.50 at 0.60 mmol/l, OR 0.15 at 1.20 mmol/l). The risk of depression decreased slightly with a concentration of 0.60 mmol/l (OR 0.83) but dropped rapidly as the concentration increased to 1.20 mmol/l (OR 0.39). By contrast, the risk for mania initially decreased steadily (OR 0.44), but decreased only marginally (OR 0.30) as the concentration increased. To reduce the recurrence risk to 56%, prevention of depression required a higher concentration than that required for mania (1.13 mmol/l vs. 0.60 mmol/l). Our results suggest a negative dose-response relationship between serum lithium levels and risk of recurrence. In particular, the different preventive effects of serum concentration on depression and mania will be an important clinical reference.
Keywords: Bipolar disorder; Dose-response meta-analysis; Lithium; Maintenance; Polarity; Serum level.
Copyright © 2022 Elsevier B.V. and ECNP. All rights reserved.
Conflict of interest statement
Declaration of competing interest Prof. Vieta has received grants and serves as a consultant, advisor, or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, SAGE, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the EU Horizon 2020, and the Stanley Medical Research Institute. Other authors declare no financial interests or potential conflicts of interest regarding the authorship and publication of this article.
Comment in
-
As in cooking, so in medicine: Doses do matter.Eur Neuropsychopharmacol. 2023 Apr;69:24-25. doi: 10.1016/j.euroneuro.2022.10.013. Epub 2023 Jan 15. Eur Neuropsychopharmacol. 2023. PMID: 36645957 No abstract available.
Similar articles
-
Lithium concentration and recurrence risk during maintenance treatment of bipolar disorder: Multicenter cohort and meta-analysis.Acta Psychiatr Scand. 2021 Oct;144(4):368-378. doi: 10.1111/acps.13346. Epub 2021 Jul 16. Acta Psychiatr Scand. 2021. PMID: 34227095 Free PMC article.
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study.J Affect Disord. 2009 Jun;115(3):466-70. doi: 10.1016/j.jad.2008.10.009. Epub 2008 Nov 20. J Affect Disord. 2009. PMID: 19019453
-
Lithium for acute mania.Cochrane Database Syst Rev. 2019 Jun 1;6(6):CD004048. doi: 10.1002/14651858.CD004048.pub4. Cochrane Database Syst Rev. 2019. PMID: 31152444 Free PMC article.
-
Lithium in bipolar disorder: can drug concentrations predict therapeutic effect?Clin Pharmacokinet. 2002;41(9):639-60. doi: 10.2165/00003088-200241090-00002. Clin Pharmacokinet. 2002. PMID: 12126457 Review.
Cited by
-
Pharmacological Strategies for Bipolar Disorders in Acute Phases and Chronic Management with a Special Focus on Lithium, Valproic Acid, and Atypical Antipsychotics.Curr Neuropharmacol. 2023;21(4):935-950. doi: 10.2174/1570159X21666230224102318. Curr Neuropharmacol. 2023. PMID: 36825703 Free PMC article.
-
Comparative effectiveness of valproic acid in different serum concentrations for maintenance treatment of bipolar disorder: A retrospective cohort study using target trial emulation framework.EClinicalMedicine. 2022 Sep 28;54:101678. doi: 10.1016/j.eclinm.2022.101678. eCollection 2022 Dec. EClinicalMedicine. 2022. PMID: 36193173 Free PMC article.
-
Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses.EClinicalMedicine. 2023 Nov 16;66:102308. doi: 10.1016/j.eclinm.2023.102308. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38045802 Free PMC article.
-
Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.JAMA Psychiatry. 2024 Feb 1;81(2):157-166. doi: 10.1001/jamapsychiatry.2023.3985. JAMA Psychiatry. 2024. PMID: 37878348 Free PMC article.
-
New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.Pharmacol Rev. 2024 May 2;76(3):323-357. doi: 10.1124/pharmrev.120.000007. Pharmacol Rev. 2024. PMID: 38697859 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical